Xu Y, Pan R L, Huang H, Wang M Z
Department of Respiratory and Critical Care Medicine, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100730, China.
Zhonghua Yu Fang Yi Xue Za Zhi. 2023 Aug 6;57(8):1176-1180. doi: 10.3760/cma.j.cn112150-20221121-01139.
The application of immune checkpoint inhibitors (ICIs) has shown impressive anti-tumor efficacy across multiple malignant tumors, leading to the prolonged survival period of tumor patients. However, immune-related adverse events should not be ignored. Checkpoint inhibitor pneumonitis (CIP) is a pulmonary adverse event that can occur in malignant tumor patients after receiving ICIs treatment. The incidence of CIP has been reported to range from 2.7% to 20.0% in clinical trials and real-world research. Furthermore, some patients might suffer from serious or fatal CIP, and the prognosis of such patients will be poor. Early detection, diagnosis and treatment may improve the prognosis of these patients. The establishment of a whole-process CIP comprehensive surveillance management mode covering the health care system and patients during ICIs treatment might be helpful to improve the early diagnosis and treatment capacity of CIP, which is a key measure to improve the prognosis of these patients.
免疫检查点抑制剂（ICIs）的应用在多种恶性肿瘤中显示出令人瞩目的抗肿瘤疗效，延长了肿瘤患者的生存期。然而，免疫相关不良事件不容忽视。检查点抑制剂肺炎（CIP）是恶性肿瘤患者接受ICIs治疗后可能发生的肺部不良事件。在临床试验和真实世界研究中，CIP的发生率据报道在2.7%至20.0%之间。此外，一些患者可能会发生严重或致命的CIP，此类患者的预后较差。早期发现、诊断和治疗可能会改善这些患者的预后。建立一个在ICIs治疗期间覆盖医疗保健系统和患者的CIP全过程综合监测管理模式，可能有助于提高CIP的早期诊断和治疗能力，这是改善这些患者预后的关键措施。
